Sarah Glynn, DO

Wake Forest Baptist Health
Winston-Salem, North Carolina

Disclosures:

• Employment: none
• Compensation: none
• Ownership: none
• Leadership: none

Presentation(s):

• 2517 - Genomic Signature for Initial Brain Metastasis Velocity (iBMV) in Non-Small Cell Lung Cancer Patients: The Elusive Biomarker to Predict the Development of Brain Metastases?

  Monday, September 30, 2024
  10:45 AM – 12:00 PM ET